Proactive Investors - Run By Investors For Investors

CytoDyn CEO updates timeline for HIV drug, addresses share dilution concerns

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive Investors the biotech is looking to submit the entirely of its Biologics License Application on its HIV drug leromlimab by the end of July, equating to being revenue-ready by end of 1Q 2020.

Pourhassan also addressed recent shareholder concerns over potential dilution of the stock.

View full CYDY profile View Profile

CytoDyn Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use